Companies › LAPIX Therapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LPX-TI641 | – | Phase 1 | Atopic Dermatitis (AD); Rheumatoid Arthritis (RA) | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06982352 | LPX-TI641 | Phase 1 | Atopic Dermatitis (AD) | Immunology | Jan 2026 |
| NCT06628206 | LPX-TI641 | Phase 1 | Rheumatoid Arthritis (RA) | Immunology | Nov 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.